TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

被引：0

作者：

Forster, M. ^{[1
]}

Krebs, M. ^{[2
,3
]}

Majem, M. ^{[4
]}

Peguero, J.

Clay, T. ^{[5
]}

Felip, E. ^{[6
]}

Iams, W. ^{[7
]}

Roxburgh, P. ^{[8
,9
]}

Doger, B. ^{[10
]}

Bajaj, P. ^{[11
]}

Kefas, J. ^{[12
]}

Scott, J. A. ^{[13
]}

Joaquin, A. Barba ^{[4
]}

Mueller, C. ^{[14
]}

Triebel, F. ^{[15
]}

机构：

[1] Univ Coll London Hosp NHS Fdn, Canc Inst, UCL, London, England

[2] Univ Manchester, Div Canc Sci, Manchester, England

[3] Christie NHS Fdn Trust, Manchester, England

[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[5] Hosp St John God Subiaco, Perth, Australia

[6] Vall Hebron Univ Hosp, Barcelona, Spain

[7] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN USA

[8] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Scotland

[9] Beatson West Scotland Canc Ctr, Glasgow, Scotland

[10] Fdn Jimenez Diaz, Madrid, Spain

[11] Tasman Oncol, Southport, Australia

[12] Univ Coll London Hosp NHS Trust, London, England

[13] Christie NHS Fdn Trust, Manchester, England

[14] Immutep GmbH, Berlin, Germany

[15] Immutep SAS, Orsay, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

LAG-3; NSCLC; PD-1/PD-L1; refractory;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.01-10

引用

页码：S395 / S395

页数：1

共 50 条

[1] Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
Majem, M.
Forster, M. D.
Krebs, M. G.
Peguero, J.
Clay, T. D.
Felip, E.
Iams, W.
Roxburgh, P.
de Speville, B. Doger
Bajaj, P.
Mueller, C.
Triebel, F.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S43 - S44
[2] Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients
Forster, M.
Felip, E.
Doger, B.
Lopez Pousa, A.
Carcereny, E.
Bajaj, P.
Church, M.
Peguero, J.
Roxburgh, P.
Triebel, F.
ANNALS OF ONCOLOGY, 2020, 31 : S667 - S667
[3] A PHASE II STUDY (TACTI-002) OF EFTILAGIMOD ALPHA (A SOLUBLE LAG-3 PROTEIN) WITH PEMBROLIZUMAB IN PD-L1 UNSELECTED PATIENTS WITH METASTATIC NON-SMALL CELL LUNG(NSCLC) OR HEAD AND NECK CARCINOMA(HNSCC)
Krebs, Matthew
Majem, Margarita
Felip, Enriqueta
Forster, Martin
Doger, Bernard
Clay, Tim
Carcereny, Enric
Peguero, Julio
Horn, Leora
Bajaj, Pawan
Roxburgh, Patricia
Brignone, Chrystelle
Mueller, Christian
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A472 - A473
[4] Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
Doger de Speville, Bernard
Felip, Enriqueta
Forster, Martin
Majem, Margarita
Bajaj, Pawan
Peguero, Julio Antonio
Carcereny, Enric
Krebs, Matthew G.
Mukherjee, Uma
Mueller, Christian
Triebel, Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma
Majem, M.
Felip, E.
Doger, B.
Akay, M.
Carcereny, E.
Clay, T.
Krebs, M. G.
Peguero, J.
Triebel, F.
ANNALS OF ONCOLOGY, 2020, 31 : S818 - S818
[6] A phase II study (TACTI-002) in first-line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
Felip, Enriqueta
Majem, Margarita
Doger, Bernard
Clay, Timothy Dudley
Carcereny, Enric
Bondarenko, Igor
Peguero, Julio Antonio
Cobo-Dols, Manuel
Forster, Martin
Ursol, Grygorii
Ledo, Gema Garcia
Vila, Laia
Krebs, Matthew
Iams, Wade Thomas
Mueller, Christian
Triebel, Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
Krebs, M. G.
Tarruella, M. Majem
Forster, M.
Peguero, J. A.
Clay, T.
Felip, E.
Iams, W.
Roxburgh, P.
de Speville, B. Doger
Bajaj, P.
Mueller, C.
Triebel, F.
ANNALS OF ONCOLOGY, 2022, 33 : S33 - S33
[8] RESULTS FROM A PHASE II STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB IN PATIENTS WITH PD-L1 UNSELECTED METASTATIC 2ND LINE HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Pousa, Antonio Lopez
Felip, Enriqueta
Forster, Martin
Doger, Bernard
Roxburgh, Patricia
Bajaj, Pawan
Peguero, Julio
Carcereny, Enric
Krebs, Matthew
Mueller, Christian
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A386 - A386
[9] A PHASE II STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB IN PATIENTS UNSELECTED FOR PD-L1 EXPRESSION IN FIRST LINE METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Peguero, Julio
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A470 - A470
[10] Initial Results from a Phase II Study (TACTI-002) in Metastatic Non-Small Cell Lung or Head and Neck Carcinoma Patients Receiving Eftilagimod Alpha (Soluble Lag-3 Protein) and Pembrolizumab
Doger, Berhard
Majem, Margarita
Felip, Eriqueta
Carcereney, Enric
Clay, Tim
Triebel, Frederic
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 213 - 214

← 1 2 3 4 5 →